Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive therapy for invasive aspergillosis in high-risk oncohematologic patients using early Aspergillus PCR detection
2010-019406-17Phase 4Completed
- Sponsor
- GETH-TC
- Start
- Jun 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of itraconazole, voriconazole, posaconazole, amphotericin b and caspofungin in aspergillosis and invasive mycoses (2 arms), sponsored by GETH-TC. Primary endpoint: Proportion of patients with proven or probable invasive fungal infection. Started Jun 2010; status: completed.
02
Drugs
itraconazolevoriconazoleposaconazoleamphotericin bcaspofungin
03
Conditions
aspergillosisinvasive mycoses
Beyond the preview
Go deeper on 2010-019406-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019406-17.